File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers

TitleThe Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers
Authors
Issue Date2015
Citation
Cancer Cell, 2015, v. 28, n. 4, p. 515-528 How to Cite?
Abstract© 2015 Elsevier Inc. Adenosine-to-inosine (A-to-I) RNA editing is a widespread post-transcriptional mechanism, but its genomic landscape and clinical relevance in cancer have not been investigated systematically. We characterized the global A-to-I RNA editing profiles of 6,236 patient samples of 17 cancer types from The Cancer Genome Atlas and revealed a striking diversity of altered RNA-editing patterns in tumors relative to normal tissues. We identified an appreciable number of clinically relevant editing events, many of which are in noncoding regions. We experimentally demonstrated the effects of several cross-tumor nonsynonymous RNA editing events on cell viability and provide the evidence that RNA editing could selectively affect drug sensitivity. These results highlight RNA editing as an exciting theme for investigating cancer mechanisms, biomarkers, and treatments.
Persistent Identifierhttp://hdl.handle.net/10722/225071
ISSN
2015 Impact Factor: 23.214
2015 SCImago Journal Rankings: 13.922

 

DC FieldValueLanguage
dc.contributor.authorHan, Leng-
dc.contributor.authorDiao, Lixia-
dc.contributor.authorYu, Shuangxing-
dc.contributor.authorXu, Xiaoyan-
dc.contributor.authorLi, Jie-
dc.contributor.authorZhang, Rui-
dc.contributor.authorYang, Yang-
dc.contributor.authorWerner, Henrica M J-
dc.contributor.authorEterovic, A. Karina-
dc.contributor.authorYuan, Yuan-
dc.contributor.authorLi, Jun-
dc.contributor.authorNair, Nikitha-
dc.contributor.authorMinelli, Rosalba-
dc.contributor.authorTsang, Yiu Huen-
dc.contributor.authorCheung, Lydia W T-
dc.contributor.authorJeong, Kang Jin-
dc.contributor.authorRoszik, Jason-
dc.contributor.authorJu, Zhenlin-
dc.contributor.authorWoodman, Scott E.-
dc.contributor.authorLu, Yiling-
dc.contributor.authorScott, Kenneth L.-
dc.contributor.authorLi, Jin Billy-
dc.contributor.authorMills, Gordon B.-
dc.contributor.authorLiang, Han-
dc.date.accessioned2016-04-18T11:16:41Z-
dc.date.available2016-04-18T11:16:41Z-
dc.date.issued2015-
dc.identifier.citationCancer Cell, 2015, v. 28, n. 4, p. 515-528-
dc.identifier.issn1535-6108-
dc.identifier.urihttp://hdl.handle.net/10722/225071-
dc.description.abstract© 2015 Elsevier Inc. Adenosine-to-inosine (A-to-I) RNA editing is a widespread post-transcriptional mechanism, but its genomic landscape and clinical relevance in cancer have not been investigated systematically. We characterized the global A-to-I RNA editing profiles of 6,236 patient samples of 17 cancer types from The Cancer Genome Atlas and revealed a striking diversity of altered RNA-editing patterns in tumors relative to normal tissues. We identified an appreciable number of clinically relevant editing events, many of which are in noncoding regions. We experimentally demonstrated the effects of several cross-tumor nonsynonymous RNA editing events on cell viability and provide the evidence that RNA editing could selectively affect drug sensitivity. These results highlight RNA editing as an exciting theme for investigating cancer mechanisms, biomarkers, and treatments.-
dc.languageeng-
dc.relation.ispartofCancer Cell-
dc.titleThe Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ccell.2015.08.013-
dc.identifier.scopuseid_2-s2.0-84944062619-
dc.identifier.volume28-
dc.identifier.issue4-
dc.identifier.spage515-
dc.identifier.epage528-
dc.identifier.eissn1878-3686-
dc.identifier.f1000725829836-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats